MedTrace Logo

Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma

NCT03572582 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2023-07-20

No results posted yet for this study

Summary

The IMMUTACE study evaluates the safety and the efficacy of the anti-programmed-death-1 antibody (anti-PD-1) nivolumab in combination with transarterial chemoembolization (TACE) in patients with multinodular, intermediate stage hepatocellular carcinoma (HCC) as first line therapy.

Conditions

  • Carcinoma, Hepatocellular
  • Hepatic Carcinoma
  • Hepatocellular Cancer

Interventions

DRUG

Nivolumab

Nivolumab therapy combined with standard TACE treatment

DRUG

TACE

TACE is performed by using drug eluting beads

Sponsors & Collaborators

Principal Investigators

  • Arndt Vogel, Prof.Dr. · Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie & Endokrinologie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-14
Primary Completion
2021-10-12
Completion
2021-12-10

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03572582 on ClinicalTrials.gov